Alnylam Pharmaceuticals, Inc. (ALNY) stock
Close on Nov 13, 2026Market cap $22.11BP/E 8.6Yield –
Alnylam Pharmaceuticals, Inc. grew revenue 56.2% to $5.01B over the twelve months to Sep 30, 2026. Operating income rose 269.3% to $977.59M, moving the operating margin from 8.2% to 19.5%. Free cash flow was $806.31M, up 382.3% from a year earlier. At the latest close the market valued the company at $22.11B, 8.6 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $22.11B
- P/E ratio
- 8.6
- Price to sales
- 4.41
- Price to book
- 6.13
- Dividend yield
- –
- Free cash flow yield
- 3.65%
Fundamentals
- Revenue
- $5.01B
- Net income
- $2.65B
- EPS, diluted
- $19.26
- Free cash flow
- $806.31M
- Book value per share
- $26.11
- Diluted shares
- 138M
Trading
- Next earnings
- Feb 11, 2027 (estimated, before the open)
- Previous close
- $156.65
- Open
- $159.17
- Day's range
- $158.82 – $168.35
- Volume
- 3,589,969
- Average volume (20 days)
- 3,285,265
- Index membership
- Nasdaq-100 (since Dec 2025), Russell 1000, Russell 3000
- Beta (5 years)
- 0.93
- 52-week range
- $149.18 – $479.79
- RSI (14 days)
- 34.6
- Volatility (1 year)
- 54.5%
- Relative volume
- 1.71×
- WACC
- 9.8%
On 1 of our idea list: Insiders buying the dip
Index membership is inferred from the holdings of funds that track each index (QQQ, IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | ALNY | S&P 500 | Difference | ALNY per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -26.3% | -3.0% | −23.2 pts | ||
| 3 months | -27.3% | -2.8% | −24.6 pts | ||
| Year to date | -58.5% | +11.5% | −70.0 pts | ||
| 1 year | -63.6% | +13.5% | −77.1 pts | ||
| 3 years | +0.0% | +77.7% | −77.7 pts | +0.0% | +21.1% |
| 5 years | -3.4% | +72.6% | −76.0 pts | -0.7% | +11.5% |
| 10 years | +254.6% | +308.2% | −53.5 pts | +13.5% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Alnylam Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- News
About Alnylam Pharmaceuticals
Pharmaceutical Preparations
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical enterprise focused on discovering and developing novel medicines utilizing ribonucleic acid interference (RNAi) to silence disease-causing genes. The company's portfolio features commercial products such as AMVUTTRA and ONPATTRO for transthyretin-mediated amyloidosis, GIVLAARI for acute hepatic porphyria, and OXLUMO for primary hyperoxaluria type 1, alongside collaborator-marketed therapies Leqvio for hypercholesterolemia and Qfitlia for hemophilia A and B. Its therapeutic solutions are designed to treat patients suffering from rare genetic ailments as well as more prevalent cardiovascular conditions.
Company profile, executives and historyAlnylam Pharmaceuticals stock: common questions
What is Alnylam Pharmaceuticals's stock price?
ALNY closed at $165.04 on Nov 13, 2026, up 5.36% on the day. Over the past 52 weeks it traded between $149.18 and $479.79.
What is Alnylam Pharmaceuticals's market cap?
Alnylam Pharmaceuticals was worth $22.11B at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is ALNY's P/E ratio?
ALNY trades at 8.6 times earnings, based on diluted earnings per share of $19.26 over the twelve months to Sep 30, 2026.
How much revenue does Alnylam Pharmaceuticals make?
Alnylam Pharmaceuticals reported revenue of $5.01B for the twelve months to Sep 30, 2026, up 56.2% from a year earlier.
Does Alnylam Pharmaceuticals pay a dividend?
No. Alnylam Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Alnylam Pharmaceuticals report earnings next?
Alnylam Pharmaceuticals is expected to report Q4 FY2026 results on Feb 11, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has ALNY stock performed over the past year?
Including dividends, ALNY returned -63.6% over the past year, against +13.5% for the S&P 500.
How many ALNY shares are sold short?
5M shares were sold short at the latest FINRA report, 4.10% of the float, or 1.9 days of average trading volume.
Who are Alnylam Pharmaceuticals's competitors?
Companies most similar to Alnylam Pharmaceuticals by business, industry and size include IONS, JAZZ, INSM, REGN, SRPT.
See a number that looks wrong?